The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer

Phase 2

Recruiting

• Conditions: Metastatic Colorectal Cancer
• Interventions: Drug: Fruquintinib+ chemotherapy; Drug: Bevacizumab+ chemotherapy

• Registration Number: NCT05555901
• Lead Sponsor: Fudan University

Brief Summary

This is a prospective, multi-center, randomized study evaluating the efficacy and safety of fruquintinib combined with chemotherapy vs bevacizumab combined with chemotherapy as second-line treatment in patients with metastatic colorectal cancer. Patients will receive fruquintinib+ FOLFIRI or bevacizumab+FOLFIRI as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine or bevacizumab+ capecitabine as maintenance treatment. All patients will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-09-22
• Study First Submitted QC: 2022-09-22
• Study First Posted: 2022-09-27
• Study Start: 2023-06-18
• Status Verified: 2023-08
• Last Update Submitted: 2023-08-27
• Last Update Posted: 2023-08-30
• Primary Completion: 2025-09
• Study Completion: 2025-09

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

• Aged 18-75years (inclusive);
• Body weight ≥40 kg;
• Histological or cytological confirmed colorectal cancer;
• Expected survival >12 weeks;
• Fail in previous first-line standard therapy, which must include a fluorouracil (5-fluorouracil or capecitabine), oxaliplatin ;
• At least one measurable lesion (according to RECIST1.1);
• Adequate hepatic, renal, heart, and hematologic functions;
• Negative serum pregnancy test at screening for women of childbearing potential.

Read More

Exclusion Criteria

• Received radiation therapy, surgical procedure, chemotherapy, immunotherapy or molecular targeted therapy, or other investigational drugs within 4 weeks prior to treatment
• Prior treatment with anti-angiogenic small molecule targeted drugs, such as fruquintinib, etc
• Prior treatment with an irinotecan-based chemotherapy regimen
• Symptomatic brain or meningeal metastases (except for patients with BMS who have received local radiotherapy or surgery for more than 6 months and whose disease is stable);
• Patients with hypertension that cannot be well controlled by antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg)
• Have obvious clinical bleeding symptoms or obvious bleeding tendency within 3 months before treatment (bleeding > 30 mL within 3 months, hematemesis, black feces, hematozoia), hemoptysis (fresh blood > 5 mL within 4 weeks), etc. Treatment for venous/venous thrombosis events within the previous 6 months, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism; Long-term anticoagulant therapy with warfarin or heparin, or long-term antiplatelet therapy (aspirin ≥300 mg/day or clopidogrel ≥75 mg/day);
• Tumor invasion of large vascular structures, such as pulmonary artery, superior vena cava or inferior vena cava, was found during screening, which was judged by the investigator to have a greater risk of bleeding;
• Active heart disease, including myocardial infarction, severe/unstable angina, 6 months prior to treatment. Echocardiography examination left ventricular ejection fraction < 50%, arrhythmia control is not good;
• The patient has had other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);
• Allergy to the study drug or any of its excipients;
• Severe infection with active or uncontrolled infection;
• Any other disease, with clinical significance of metabolic abnormalities, abnormal physical examination or laboratory abnormalities, according to researchers, there is reason to suspect the patient has not suitable for the use of study drugs of a disease or condition (such as have a seizure and require treatment), or will affect the interpretation of results, or to make patients in high-risk situations;
• Urine routine showed urine protein ≥2+, and 24-hour urine protein level >1.0g.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Fruquintinib+ chemotherapy	Fruquintinib+ chemotherapy	Patients will receive fruquintinib+ FOLFIRI once every four weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive fruquintinib + capecitabine as maintenance treatment.
Bevacizumab+ chemotherapy	Bevacizumab+ chemotherapy	Patients will receive bevacizumab+ FOLFIRI once every two weeks as the second-line treatment. After receiving 4-6 months of second-line treatment, patients who achieve disease control will receive bevacizumab + capecitabine as maintenance treatment.

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS)	from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year	time from randomization to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator

Secondary Outcome Measures

Name	Time	Method
Disease Control Rate (DCR)	from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year	the proportion of patients with complete response, partial response or stable disease, using RECIST v 1.1.
Objective response rate (ORR)	from randomization up to progressive disease or EOT due to any cause, assessed up to 1 year	the proportion of patients with complete response or partial response, using RECIST v 1.1.
Overall survival (OS)	from randomization until death due to any cause, assessed up to 2 year	time from randomization to death from any cause.

Trial Locations

Locations (13)

Xiangya Hospital of Central South University; 🇨🇳 Changsha, Hunan, China

the Second Affiliated Hospital of Medical College of Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China

The Fourth Hospital of Hebei Medical University and Hebei Tumor Hospital; 🇨🇳 Shijiazhuang, Hebei, China

Henan Cancer Hospital; 🇨🇳 Zhengzhou, Henan, China

Qilu Hospital of Shandong University (QLH); 🇨🇳 Jinan, Shandong, China

Ruijin Hospital Affiliated to The Shanghai Jiao Tong University Medical School; 🇨🇳 Shanghai, Shanghai, China

Zhejiang Provincial People's Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Sir Run Run Shaw Hospital; 🇨🇳 Hangzhou, Zhejiang, China

Zhongshan hosptial, Fudan University; 🇨🇳 Shanghai, China

The First Hospital of Putian City; 🇨🇳 Putian, Fujian, China

The Affiliated Hospital of Qingdao University; 🇨🇳 Qingdao, Shandong, China

Changhai Hospital; 🇨🇳 Shanghai, Shanghai, China

Renji hospital, Shanghai Jiaotong University; 🇨🇳 Shanghai, Shanghai, China